MAP2K7 and acute lymphoblastic leukemia: Moreover, both MEK/ERK and p38 MAPK kinase promoted T-ALL migration through interactions with α2β1 integrin, suggesting that this blockade could be a valuable target for T-ALL therapeutic treatment (56).